European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111

Vaccines Communication Immunity Immunization 111

pharmaphorum

JULY 6, 2021

The new figures – from the BioIndustry Association and Clarivate – were dominated by more than £1 billion in venture capital funding for UK biotech and life sciences companies, headlined by DNA sequencing company Oxford Nanopore’s £195 million raise in May that was just shy of the £205 million record set by Immunocore in 2005.

Documentation 141

Documentation Vaccines 141

Pharma in Brief

JANUARY 10, 2024

The Guidance was last updated in 2005. It now contemplates IT platforms ( e.g. , social media) and applies to drugs for use in humans as well as medical devices, natural health products, biologics, vaccines, and animal health products. Rare disease strategy. The PMPRB intends to finalize its new guidelines in 2024.

Drug Pricing 52

Drug Pricing Documentation Biosimilars Vaccines 52

Pharmaceutical Technology

OCTOBER 28, 2022

Quality by design (QbD) is a concept introduced into the pharmaceutical regulatory lexicon in 2005. QbD principles are woven into regulatory guidance documents, primarily guidances Q8 to Q11 of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).

Biosimilars 52

Biosimilars Vaccines Drug Development Documentation 52

Pharmaceutical Technology

APRIL 27, 2023

The successful development and deployment of the mRNA-based COVID-19 vaccines has catalysed the biopharma industry and paved the way to expand this drug modality to new therapeutic areas. Excluding vaccines, there are five mRNA therapeutic products in clinical trial development as of November 2022.

Vaccines 52

Vaccines Drug Development Documentation Communication 52